250 related articles for article (PubMed ID: 25395200)
1. Clinically used selective oestrogen receptor modulators increase LDL receptor activity in primary human lymphocytes.
Cerrato F; Fernández-Suárez ME; Alonso R; Alonso M; Vázquez C; Pastor O; Mata P; Lasunción MA; Gómez-Coronado D
Br J Pharmacol; 2015 Mar; 172(5):1379-94. PubMed ID: 25395200
[TBL] [Abstract][Full Text] [Related]
2. Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport.
Fernández-Suárez ME; Escolà-Gil JC; Pastor O; Dávalos A; Blanco-Vaca F; Lasunción MA; Martínez-Botas J; Gómez-Coronado D
Sci Rep; 2016 Sep; 6():32105. PubMed ID: 27601313
[TBL] [Abstract][Full Text] [Related]
3. Synergistic upregulation of low-density lipoprotein receptor activity by tamoxifen and lovastatin.
Suárez Y; Fernández C; Gómez-Coronado D; Ferruelo AJ; Dávalos A; Martínez-Botas J; Lasunción MA
Cardiovasc Res; 2004 Nov; 64(2):346-55. PubMed ID: 15485695
[TBL] [Abstract][Full Text] [Related]
4. Comparing the effects of 17β-oestradiol and the selective oestrogen receptor modulators, raloxifene and tamoxifen, on prepulse inhibition in female rats.
Gogos A; van den Buuse M
Schizophr Res; 2015 Nov; 168(3):634-9. PubMed ID: 25979306
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
6. Selective estrogen receptor modulators (SERMs) affect cholesterol homeostasis through the master regulators SREBP and LXR.
Fernández-Suárez ME; Daimiel L; Villa-Turégano G; Pavón MV; Busto R; Escolà-Gil JC; Platt FM; Lasunción MA; Martínez-Botas J; Gómez-Coronado D
Biomed Pharmacother; 2021 Sep; 141():111871. PubMed ID: 34225017
[TBL] [Abstract][Full Text] [Related]
7. From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators.
Hussein MH; Schneider EK; Elliott AG; Han M; Reyes-Ortega F; Morris F; Blastovich MAT; Jasim R; Currie B; Mayo M; Baker M; Cooper MA; Li J; Velkov T
Microb Drug Resist; 2017 Jul; 23(5):640-650. PubMed ID: 27935770
[TBL] [Abstract][Full Text] [Related]
8. The cardiovascular effects of selective estrogen receptor modulators.
Christodoulakos GE; Lambrinoudaki IV; Botsis DC
Ann N Y Acad Sci; 2006 Dec; 1092():374-84. PubMed ID: 17308162
[TBL] [Abstract][Full Text] [Related]
9. Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.
Suuronen T; Nuutinen T; Huuskonen J; Ojala J; Thornell A; Salminen A
Inflamm Res; 2005 May; 54(5):194-203. PubMed ID: 15953991
[TBL] [Abstract][Full Text] [Related]
10. Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.
Park WC; Jordan VC
Trends Mol Med; 2002 Feb; 8(2):82-8. PubMed ID: 11815274
[TBL] [Abstract][Full Text] [Related]
11. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro.
Nuttall ME; Fisher PW; Suva LJ; Gowen M
Eur J Cancer; 2000 Sep; 36 Suppl 4():S63-4. PubMed ID: 11056323
[TBL] [Abstract][Full Text] [Related]
12. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.
Gajdos C; Jordan VC
Clin Breast Cancer; 2002 Jan; 2(4):272-81. PubMed ID: 11899358
[TBL] [Abstract][Full Text] [Related]
13. A pharmacological review of selective oestrogen receptor modulators.
Goldstein SR; Siddhanti S; Ciaccia AV; Plouffe L
Hum Reprod Update; 2000; 6(3):212-24. PubMed ID: 10874566
[TBL] [Abstract][Full Text] [Related]
14. Searching for an ideal SERM: Mining tamoxifen structure-activity relationships.
Price S; Bender SG; Yahn R; Till NA; Varady S; LaLonde RL
Bioorg Med Chem Lett; 2021 Nov; 52():128383. PubMed ID: 34592434
[TBL] [Abstract][Full Text] [Related]
15. Lovastatin increases surface low density lipoprotein receptor expression by retarding the receptor internalization rate in proliferating lymphocytes.
Chan PC; Lafrenière R; Parsons HG
Biochem Biophys Res Commun; 1997 Jun; 235(1):117-22. PubMed ID: 9196047
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of testosterone propionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat.
Pinilla L; Barreiro ML; Gonzalez LC; Tena-Sempere M; Aguilar E
J Endocrinol; 2002 Mar; 172(3):441-8. PubMed ID: 11874692
[TBL] [Abstract][Full Text] [Related]
17. Assessment of functional low-density lipoprotein receptor activity on lymphocytes of normal subjects and patients with familial hypercholesterolemia.
Cuthbert JA; Lipsky PE
Trans Assoc Am Physicians; 1988; 101():1-11. PubMed ID: 3269672
[TBL] [Abstract][Full Text] [Related]
18. [Selective estrogen receptor modulators (SERMs) in the practice].
Nagykálnai T
Magy Onkol; 2002; 46(2):165-75. PubMed ID: 12202896
[TBL] [Abstract][Full Text] [Related]
19. Identification of low density lipoprotein receptor abnormalities by assaying functional receptors on proliferating lymphocytes.
Cuthbert JA; Lipsky PE
Arteriosclerosis; 1989; 9(1 Suppl):I43-9. PubMed ID: 2912432
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomised rat uterus.
Green AR; Parrott EL; Butterworth M; Jones PS; Greaves P; White IN
J Endocrinol; 2001 Sep; 170(3):555-64. PubMed ID: 11524235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
